Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Open-label, Randomized, Two-part, Two-treatment, Two-period Crossover Study to Investigate the Effect of Gemfibrozil or Rifampicin on the Pharmacokinetics of Selexipag and Its Metabolite ACT-333679 in Healthy Male Subjects.

Next Previous
Search
Trial Profile

A Single-center, Open-label, Randomized, Two-part, Two-treatment, Two-period Crossover Study to Investigate the Effect of Gemfibrozil or Rifampicin on the Pharmacokinetics of Selexipag and Its Metabolite ACT-333679 in Healthy Male Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selexipag (Primary) ; Gemfibrozil; Rifampicin
  • Indications Arteriosclerosis obliterans; Pulmonary arterial hypertension; Pulmonary hypertension; Raynaud's disease
  • Focus Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals

    • Most Recent Events

    • 17 Jul 2017 Results published in the British Journal of Clinical Pharmacology
    • 27 Jun 2017 Results (n=20) from part II of the study assessing the effect of rifampicin on the pharmacokinetics of selexipag and ACT-333679, presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics
    • 27 Jun 2017 Results (n=20) from part I of the study assessing the effect of gemfibrozil on the pharmacokinetics of selexipag and ACT-333679, presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top